CCL2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2604676	0.35	4/20
SCHEMBL1901895	0.64	3/20
SCHEMBL1898913	0.58	3/20
SCHEMBL223440	0.58	3/20
SCHEMBL1901576	0.56	3/20
SCHEMBL1905964	0.56	3/20
SCHEMBL1907682	0.54	3/20
SCHEMBL1906317	0.53	3/20
SCHEMBL1907797	0.51	3/20
SCHEMBL224475	0.45	3/20
Hydroxyfasudil (SCHEMBL123699)	1.00	2/20
SCHEMBL223142	0.75	2/20
SCHEMBL224646	0.75	2/20
SCHEMBL1271163	0.73	2/20
SCHEMBL566377	0.71	2/20
SCHEMBL2869228	0.70	2/20
Hydrochloric Acid (SCHEMBL574657)	0.70	2/20
Hydrochloric Acid (SCHEMBL1981350)	0.70	2/20
SCHEMBL567383	0.69	2/20
Hydrochloric Acid (SCHEMBL1848494)	0.69	2/20

Clinical trials — most relevant to CCL2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar	PHASE2/PHASE3	UNKNOWN
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia	PHASE3	SUSPENDED
Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms	PHASE3	UNKNOWN
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation	PHASE3	SUSPENDED
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients	PHASE1/PHASE2	COMPLETED
Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer	PHASE2	UNKNOWN
A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36	PHASE1	COMPLETED
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)	PHASE1	RECRUITING
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation	PHASE1	COMPLETED
NIH CCR2 AAA Study	EARLY_PHASE1	COMPLETED
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Inflammatory Biomarkers in Seizure	nan	UNKNOWN
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure	nan	UNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination.	nan	ENROLLING_BY_INVITATION
Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker	nan	COMPLETED
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA	nan	RECRUITING
Value of Various Chemokines in the Detection and Follow up of RCC	nan	UNKNOWN
Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients	nan	UNKNOWN
The Eswatini Study on Neurocognitive Performance in Adolescents Living With HIV	nan	NOT_YET_RECRUITING
Lung-Resident Memory Th2 Cells in Asthma	nan	ACTIVE_NOT_RECRUITING
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma	nan	UNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage	nan	ENROLLING_BY_INVITATION
Inflammatory Cytokines in GCF and Placental Tissues in Chronic Periodontitis Patients With Preterm Delivery	nan	COMPLETED
The Relationship Between Serum Chemokine Ligand 21 (CCL-21) Level and Disease Activity	nan	NOT_YET_RECRUITING
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
The Role of Granulation Tissue in Periodontal Regeneration	nan	RECRUITING
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
Fetal Cell Receptors Repertoire	nan	RECRUITING
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCL2 binder may also engage these)

Protein	Name	Similarity
Q5RA36	—	1.000	Q5RA36 →
P52203	—	1.000	P52203 →
P61274	—	0.999	P61274 →
Q9TTQ3	—	0.999	Q9TTQ3 →
P61275	—	0.999	P61275 →
P28291	—	0.998	P28291 →
Q68AY9	—	0.997	Q68AY9 →
P80075	—	0.995	P80075 →
P42831	—	0.994	P42831 →
Q8MIT7	—	0.993	Q8MIT7 →
P49873	—	0.992	P49873 →
Q68Y88	—	0.991	Q68Y88 →
Q09141	—	0.991	Q09141 →
CCL11	Eotaxin	0.990	landscape →
P80098	—	0.989	P80098 →
Q9QXY8	—	0.987	Q9QXY8 →
Q99616	—	0.987	Q99616 →
Q9TTQ4	—	0.987	Q9TTQ4 →
Q9WUZ6	—	0.986	Q9WUZ6 →
Q9TTS6	—	0.985	Q9TTS6 →
P48298	—	0.983	P48298 →
O88430	—	0.981	O88430 →
Q8HYP9	—	0.981	Q8HYP9 →
P55774	—	0.981	P55774 →
Q03366	—	0.980	Q03366 →
Q62401	—	0.979	Q62401 →
Q92583	—	0.979	Q92583 →
P28292	—	0.979	P28292 →
Q8I021	—	0.979	Q8I021 →
Q9Y258	—	0.979	Q9Y258 →